Oxford, United Kingdom & San Jose, California | April 9, 2026
Oxford BioTherapeutics (OBT) has announced a strategic collaboration with Bristol Myers Squibb (BMS) to discover and develop next-generation T-cell engager therapies for solid tumours, marking a significant advancement in precision oncology and immunotherapy innovation. The multi-year agreement leverages OBT’s proprietary OGAP®-Verify discovery platform alongside BMS’s global expertise in oncology development and commercialization, aiming to accelerate the identification of novel tumour-selective targets and deliver highly differentiated therapeutic candidates. This partnership reinforces the growing importance of platform-driven drug discovery and highlights continued investment in targeted cancer therapies addressing unmet medical needs.
Platform-Driven Discovery Accelerates Oncology Innovation
At the core of this collaboration is OBT’s OGAP®-Verify platform, a cutting-edge technology designed to enable highly sensitive and specific identification of tumour-associated targets suitable for drug development. By combining advanced target discovery, validation, and molecular engineering capabilities, OBT will lead the identification of new cancer targets and the generation of next-generation T-cell engager molecules, which are engineered to redirect immune cells to attack cancer cells.
This approach enhances the potential for precision immuno-oncology therapies, improving both efficacy and safety by selectively targeting tumour-specific antigens. The collaboration reflects a broader shift in the biopharmaceutical industry toward data-driven, platform-enabled discovery models that increase the probability of success in early-stage development.
Strategic Collaboration Strengthens Drug Development Pipeline
Advertisement
Under the terms of the agreement, OBT will be responsible for the design and delivery of development-ready candidates, marking its evolution into a fully integrated discovery and preclinical development organization, while BMS will lead clinical development, regulatory progression, and global commercialization. The deal includes an upfront payment, research funding, milestone payments, and potential royalties on future product sales, reflecting the significant commercial and therapeutic potential of the collaboration.
Notably, this marks OBT’s third major pharmaceutical partnership within 12 months, following previous collaborations with global leaders, further validating the strength of its platform and pipeline capabilities. This partnership underscores the critical role of biopharma alliances in accelerating innovation and reducing development timelines in oncology.
Advancing Next-Generation Immuno-Oncology Therapies
The focus on T-cell engager therapies represents a rapidly growing area of cancer treatment, enabling the immune system to recognize and eliminate tumour cells more effectively. These therapies are part of a broader class of immuno-oncology (IO) strategies, which include bispecific antibodies and antibody-drug conjugates (ADCs), designed to improve patient outcomes in difficult-to-treat cancers.
By integrating OBT’s discovery capabilities with BMS’s clinical and commercial expertise, the collaboration aims to deliver innovative, scalable, and clinically impactful therapies that can address the complexity of solid tumours. This initiative aligns with global efforts to expand the reach of precision medicine and targeted immunotherapies, offering new hope for patients with limited treatment options.
The partnership between Oxford BioTherapeutics and Bristol Myers Squibb represents a significant step forward in the development of next-generation cancer therapies, combining advanced discovery platforms, strategic collaboration, and translational research expertise to accelerate innovation in oncology. By focusing on tumour-selective targets and immune-based therapeutic strategies, this collaboration highlights the future direction of cancer treatment and the increasing reliance on integrated biopharmaceutical ecosystems.
As the program progresses toward clinical development, it reinforces the importance of platform validation, early-stage innovation, and collaborative R&D models in delivering effective and scalable solutions to global healthcare challenges.
Source: Oxford BioTherapeutics, Bristol Myers Squibb press release
